IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells

Research output: Contribution to journalArticlepeer-review

Standard Standard

IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells. / Perks, Claire; Vernon, Ellen; Rosendahl, Ann et al.
In: Oncogene, Vol. 26, No. 40, 30.08.2007, p. 5966-72.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

Perks, C, Vernon, E, Rosendahl, A, Tonge, D & Holly, J 2007, 'IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells', Oncogene, vol. 26, no. 40, pp. 5966-72. https://doi.org/10.1038/sj.onc.1210397

APA

Perks, C., Vernon, E., Rosendahl, A., Tonge, D., & Holly, J. (2007). IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells. Oncogene, 26(40), 5966-72. https://doi.org/10.1038/sj.onc.1210397

CBE

MLA

VancouverVancouver

Perks C, Vernon E, Rosendahl A, Tonge D, Holly J. IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells. Oncogene. 2007 Aug 30;26(40):5966-72. Epub 2007 Mar 17. doi: 10.1038/sj.onc.1210397

Author

Perks, Claire ; Vernon, Ellen ; Rosendahl, Ann et al. / IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells. In: Oncogene. 2007 ; Vol. 26, No. 40. pp. 5966-72.

RIS

TY - JOUR

T1 - IGF-II and IGFBP-2 Differentially Regulate PTEN in Human Breast Cancer Cells

AU - Perks, Claire

AU - Vernon, Ellen

AU - Rosendahl, Ann

AU - Tonge, D

AU - Holly, Jeff

PY - 2007/8/30

Y1 - 2007/8/30

N2 - The dual-function phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II (IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein (IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways.

AB - The dual-function phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II (IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein (IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways.

U2 - 10.1038/sj.onc.1210397

DO - 10.1038/sj.onc.1210397

M3 - Article

VL - 26

SP - 5966

EP - 5972

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 40

ER -